HeimBNTX • NASDAQ
add
BioNTech SE - ADR
96,25 $
Eftir lokun(0,00%)0,00
96,25 $
Lokað: 5. des., 16:00:28 GMT-5 · USD · NASDAQ · Lagalegir fyrirvarar
Við síðustu lokun
96,00 $
Dagbil
95,21 $ - 96,69 $
Árabil
81,20 $ - 129,27 $
Markaðsvirði
23,14 ma. USD
Meðalmagn
1,05 m.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (EUR) | sep. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 1,52 ma. | 22,02% |
Rekstrarkostnaður | 1,40 ma. | 34,32% |
Nettótekjur | -28,70 m. | -114,49% |
Hagnaðarhlutfall | -1,89 | -111,88% |
Hagnaður á hvern hlut | -0,12 | -114,81% |
EBITDA | 91,20 m. | 39,66% |
Virkt skatthlutfall | 216,19% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (EUR) | sep. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 14,53 ma. | -13,06% |
Heildareignir | 21,34 ma. | -4,73% |
Heildarskuldir | 2,86 ma. | -12,87% |
Eigið fé alls | 18,48 ma. | — |
Útistandandi hlutabréf | 240,46 m. | — |
Eiginfjárgengi | 1,25 | — |
Arðsemi eigna | -0,38% | — |
Ávöxtun eigin fjár | -0,44% | — |
Peningaflæði
Breyting á handbæru fé
| (EUR) | sep. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | -28,70 m. | -114,49% |
Handbært fé frá rekstri | 780,70 m. | 222,19% |
Reiðufé frá fjárfestingum | -925,30 m. | -551,16% |
Reiðufé frá fjármögnun | -11,50 m. | -45,57% |
Breyting á handbæru fé | -176,60 m. | 76,52% |
Frjálst peningaflæði | 1,05 ma. | 253,59% |
Um
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Framkvæmdastjóri
Stofnsett
2008
Vefsvæði
Starfsfólk
6.772
